85 related articles for article (PubMed ID: 10485665)
1. From the Food and Drug Administration.
Henney JE
JAMA; 1999 Sep; 282(10):932. PubMed ID: 10485665
[No Abstract] [Full Text] [Related]
2. Anticipated US approval for rosiglitazone and pioglitazone.
Diabetes Obes Metab; 1999 May; 1(3):181-2. PubMed ID: 11220298
[No Abstract] [Full Text] [Related]
3. Warner Lambert/Sankyo diabetes drug nears market.
Nat Biotechnol; 1997 Feb; 15(2):113. PubMed ID: 9035120
[No Abstract] [Full Text] [Related]
4. Diabetes recall. Though Rezulin's withdrawal is a blow for some patients, there are ways to cope. Here's how.
Gorman C
Time; 2000 Apr; 155(13):94. PubMed ID: 11009709
[No Abstract] [Full Text] [Related]
5. FDA approves pioglitazone for diabetes.
Miller JL
Am J Health Syst Pharm; 1999 Sep; 56(17):1698. PubMed ID: 10512494
[No Abstract] [Full Text] [Related]
6. Rosiglitazone approved for treatment of type 2 diabetes.
Miller JL
Am J Health Syst Pharm; 1999 Jul; 56(13):1292, 1294. PubMed ID: 10683120
[No Abstract] [Full Text] [Related]
7. Pharmacologic therapy for type 2 diabetes mellitus.
DeFronzo RA
Ann Intern Med; 2000 Jul; 133(1):73-4. PubMed ID: 10877745
[No Abstract] [Full Text] [Related]
8. [Thiazolidinediones in type 2 diabetes].
Baum U
Med Monatsschr Pharm; 2000 Jul; 23(7):210-3. PubMed ID: 10941251
[No Abstract] [Full Text] [Related]
9. Avandia, a leading alternative for Rezulin patients, prescribed to more than 700,000 patients.
Diabetes Technol Ther; 2000; 2(2):292. PubMed ID: 11469275
[No Abstract] [Full Text] [Related]
10. Actos (pioglitazone HCL) provides a safe, effective alternative for patients formerly taking Rezulin.
Diabetes Technol Ther; 2000; 2(2):290-1. PubMed ID: 11469274
[No Abstract] [Full Text] [Related]
11. Troglitazone for non-insulin-dependent diabetes mellitus.
Med Lett Drugs Ther; 1997 May; 39(1001):49-51. PubMed ID: 9164446
[No Abstract] [Full Text] [Related]
12. Rosiglitazone and type 2 diabetes mellitus.
Bragg T
Lancet; 2001 May; 357(9266):1451. PubMed ID: 11360960
[No Abstract] [Full Text] [Related]
13. NICE issues guidance on diabetes treatments.
Iles A
BMJ; 2003 Sep; 327(7414):520. PubMed ID: 12958096
[No Abstract] [Full Text] [Related]
14. Rosiglitazone monotherapy and type 2 diabetes.
Lawrence IG
Diabet Med; 2001 Nov; 18 Suppl 4():6-8. PubMed ID: 11989215
[No Abstract] [Full Text] [Related]
15. Warner-Lambert voluntarily withdraws Rezulin.
Diabetes Technol Ther; 2000; 2(2):290. PubMed ID: 11469273
[No Abstract] [Full Text] [Related]
16. [Oral therapy in type 2 diabetes. Critical evaluation of glitazones].
Lotz N
MMW Fortschr Med; 2002 Jan; 144(3-4):48-50. PubMed ID: 11862793
[No Abstract] [Full Text] [Related]
17. Troglitazone: a new class of oral antihyperglycemic for the treatment of type II diabetes.
Teter ML
Nurse Pract; 1997 Jul; 22(7):119-21. PubMed ID: 9253019
[No Abstract] [Full Text] [Related]
18. Thiazolidinediones: a comparative review of approved uses.
Sood V; Colleran K; Burge MR
Diabetes Technol Ther; 2000; 2(3):429-40. PubMed ID: 11467345
[TBL] [Abstract][Full Text] [Related]
19. Rezulin to be withdrawn from the market.
Diabetes Technol Ther; 2000; 2(2):289. PubMed ID: 11469272
[No Abstract] [Full Text] [Related]
20. [Troglitazone, an insulin action enhancer--a drug of precision to treat adult-onset diabetes].
Westerbacka J; Yki-Järvinen H
Duodecim; 1997; 113(19):1847-8. PubMed ID: 10892078
[No Abstract] [Full Text] [Related]
[Next] [New Search]
